“and Ardian will start ramping through '26.”

In context

“question. I'm going to -- first of all, good question, as Danielle pointed out, and I will take the first part of it and then hand it to Thierry to go through the earnings stuff. But on the growth side, look, we're very bullish on the growth drivers. We -- even in the markets that we're in and the growth drivers that we have. So like even in Q4, our markets grew 7%, even without diabetes. And we've got strong positions in these markets, and we see growth from our big three portfolios to be mid-single and then some. We're running the company at higher expectations than we're guiding here. Just some examples. I mean you see our CV business accelerating to 8% with nearly 30% growth in cash, which added -- just that alone added 70 basis points to the company growth. And that's without Ardian, and Ardian will start ramping through '26. You got neuroscience with double-digit growth in Neuromod and look, CST, what can I say? I mean, it's just separating itself from the pack. And we've got Tibial coming in Pelvic Health. And so we've got some growth drivers there, of course, in surgical, Hugo, as we talked about the commentary's building momentum, and we'll start to have more of a meaningful impact on med-surg next year. and then beyond that on the company. So we're bullish about the markets that we're in, the positions we have in those markets and our growth potential. So that's what's baked into the next year's guide and going into '27. I mean, we're at the early stages of these growth drivers with more to come. On the earnings, I'll turn it over to Thierry. Anything else you want to add on growth. Thierry Pieton: No, th”